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Review Article
The increasing knowledge about limb girdle muscular 
dystrophy (LGMD) has clariÞ ed many aspects of this extensive 
group of neuromuscular conditions and has moreover proven 
their wide clinical and genetic heterogeneity. For these 
reasons, achieving a precise diagnosis of a particular type 
of LGMD may be still difÞ cult and requires a comprehensive 
approach, which includes epidemiology, medical history, 
clinical examination, laboratory and genetic tests. All of the 
LGMDs are individually rare and their population frequency 
is highly variable. The prevalence of the different forms of 
LGMD in different populations has to be considered for the 
differential diagnosis. Some characteristic clinical features 
may help to distinguish subtypes of LGMD however protein 
analysis on muscle biopsy and genetic testing still represent 
the gold standard in the diagnosis of these muscular 
dystrophies. Reaching a precise diagnosis in all patients 
is important to allow genetic counseling to be properly 
applied and to direct appropriate medical management with 
a potential positive impact on the length and quality of life. 
Moreover, new speciÞ c therapeutic approaches, including 
limited local gene therapy, have been emerging over the 
last few years and require a precise genetic deÞ nition of the 
conditions. This article will concentrate on the diagnostic 
process by which these disorders can be deÞ ned and the 
implications of making these diagnoses.
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Introduction
Trying to reach a precise diagnosis in a patient with 
a suspected limb girdle muscular dystrophy (LGMD) 
is traditionally regarded as difficult. Although the 
increasing knowledge about the genetic basis of the 
different diseases in this group has made the group seem 
rather complicated, it also allows us the possibility of 
reaching a proper diagnosis. The diagnostic process 
needs to take into account the clinical history and 
examination of the patient, as well as a combination 
of possible specialized analysis of the muscle biopsy 
and DNA. 
A possible diagnosis of LGMD should be considered in 
a patient with muscular dystrophy having predominant 
involvement of the limb-girdle (pelvic and shoulder) 
musculature. However, these clinical findings are 
not unique to the LGMDs and other neuromuscular 
disorders such as Becker muscular dystrophy, late onset 
spinal muscular atrophy, myotonic dystrophy Type 2, 
Bethlem myopathy and Pompes disease may all show 
overlapping clinical features and rarer disorders such 
as congenital myasthenic syndromes may also need 
to be considered in the differential diagnosis. On the 
other hand, for many of the genes involved in LGMDs, 
a broad heterogeneity of clinical presentation and 
muscle involvement has emerged. This is particularly 
true for some of the dominant disorders in the LGMD 
classification, such as LGMD1A where myotilin 
mutations are associated also with the disorders known 
as the myofibrillar myopathies,[1-2] LGMD1B where lamin 
A/C mutations can also cause a wide range of diseases[3-4] 
and LGMD1C where the clinical presentation includes 
hyperCKaemia, rippling muscle disease, myalgia and 
distal myopathy.[5-6] This means that there needs to be 
a high level of suspicion in this group of disorders if 
the correct diagnosis is going to be reached. 
The molecular basis of the diseases is also highly 
heterogeneous. The process of gene identification in 
LGMDs has involved a combination of linkage and 
candidate gene analysis, resulting in a gene and protein-
based classification which includes three known 
genes causing autosomal dominant LGMDs[7] and 14 
known genes causing autosomal recessive LGMDs[8,9] 
[Table 1].
The genes and proteins causing the diseases in these 
groups show a huge range of localization across the 
muscle fiber, from sarcolemma to nuclear envelope, 
with functions ranging from structural to enzymatic. 
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Despite several comprehensive studies developed over 
the last few years, the genetic etiology of many cases of 
LGMD is not yet known.
Considering the wide clinical and genetic variability 
of LGMDs, achieving a precise diagnosis, especially 
in sporadic patients, may be difficult and requires 
a comprehensive clinical and laboratory approach. 
The definition of a precise diagnosis is increasingly 
allowing directed management for these diseases by 
the ability to predict specific complications such as 
those of the cardiac or respiratory systems.[10]
Proper genetic counseling can only be offered if the 
precise mode of inheritance is known which often 
depends on a genetic diagnosis and prenatal diagnosis 
can only be provided if the underlying molecular 
defect for the condition is known. Finally, in the future 
a precise genetic diagnosis will be the starting point 
for specific gene and protein-based therapies.
This article will concentrate on the diagnostic 
process by which these disorders can be defined and 
the implications of making these diagnoses.
History and Examination
Limb girdle muscular dystrophy (LGMD) was 
first designated as a disease group to address a set 
of patients with predominantly proximal muscle 
weakness and a dystrophic pattern on muscle biopsy. 
It separated them from the more classically recognized 
Duchenne/ Becker and facioscapulohumeral 
muscular dystrophies, both of which are much more 
common than LGMDs in most populations, and for 
which relatively straightforward diagnostic tests now 
exist. The key hallmarks of LGMD remain the marked 
weakness of the pelvic and shoulder girdle muscles; 
however, limb girdle muscle weakness is a primary 
problem in a large number of patients with very 
variable underlying muscular conditions. Moreover, 
the clinical course of LGMD ranges from severe forms 
with early onset and rapid progression to milder forms 
with late onset.
As the different disease entities within the group 
have become better defined based on their distinct 
genetic basis, accompanying clinical features may 
help to distinguish subtypes of LGMD.[11] Particular 
features which need to be paid attention to include 
muscle hypertrophy or atrophy, scapular winging, 
muscle rippling and contractures. While the history 
will in many cases be a relatively nonspecific story of 
progressive proximal weakness, with onset at any age, 
there are some clues in the history of onset which can 
be very suggestive of a particular diagnosis. Onset, 
distribution of muscle weakness and wasting and 
other characteristic clinical features can also help 
in the differential diagnosis of the different forms of 
LGMD [Table 2].
Autosomal dominant limb girdle muscular dystrophy 
(LGMD1)
Most of the autosomal dominant LGMDs have 
been described in single extended pedigrees and are 
considered very rare. Moreover, among the genetic 
causes of the autosomal dominant LGMDs, pure limb-
girdle weakness appears to be a rare phenotype while 
presentations with a distal myopathy or myofibrillar 
myopathy are increasingly recognized. The variability 
in presentation for all of the LGMDs means that different 
family members, or indeed the same individual, may 
present with one or more manifestations of mutation 
in a particular gene. Consequently, in some of the 
autosomal dominant types of LGMD the family history 
may be particularly informative for the diagnosis. For 
example, the presence of respiratory failure, dysarthria 
or cardiomyopathy in the index case or wider family 
may help to suggest LGMD1A.[12] History of arrhythmia 
or contractures can be suggestive of laminopathy or 
LGMD1B,[13] while a history of muscle rippling or 
myalgia may be suggestive of LGMD1C[14] [Table 2]. 
LGMD2A
The clinical examination and a careful observation of 
the pattern of muscle weakness may be very helpful in 
recognizing this particular type of LGMD. In particular, 
a striking and early involvement of the posterior thigh 
muscles (adductors, semimembranosus and vastus 
intermedius muscles) with relative sparing of the 
vastus lateralis, sartorius and gracilis[15] appears to be 
almost stereotypic of calpainopathy. The presence of 
early contractures, scapular winging and preserved 
respiratory function is in contradiction to most other 
types of LGMD and can be very helpful in pinpointing 
the diagnosis.[16] Patients typically lose independent 
ambulation between 11 and 28 years after onset of the 
condition however disease progression in LGMD2A can 
be widely variable.[17]
LGMD2B
The clinical phenotype of dysferlinopathies is widely 
variable ranging from typical LGMD2B to Miyoshi 
Myopathy (MM) and distal anterior compartment 
myopathy (DMAT).[18] Over the last year other clinical 
presentations associated with mutations in the DYSF 
gene have been described, including an intermediate 
form with proximal and distal weakness from onset 
and patients with rigid spine and leg muscle stiffness 
with onset in the sixth decade.[19-21] Involvement of the 
shoulder girdle is usually a later event, although local 
biceps atrophy may be present at an early stage of the 
disease. Around 10% of LGMD2B patients experiences 
muscle pain and swelling, especially in the calves.
A history of normal childhood activities or even 
outstanding sporting ability until a relatively sudden 
onset in the late teens of muscle difficulties, often 
Bushby, et al.: Limb girdle muscular dystrophy
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Table 2: The LGMDs: Clinical features and type-speciÞ c management
Type of LGMD Gene Relative prevalence/ Other phenotypes Age at onset Key features 
 product fonder mutations   from history 
LGMD1A Myotilin Common mutation in  MyoÞ brillar myopathy Adulthood May be 
  all populations   dysarthria, tight TAs,  
     swallowing difÞ culties.  
     Distal weakness 
LGMD1B Lamin A/C Present worldwide:  Dilated cardiomyopathy, Any age May be family history 
  private mutations usual CMT, progeria, mandibuloacral   of sudden death 
   dysplasia, lipodystrophy,    
   overlapping phenotypes    
       
      
      
LGMD1C Caveolin3 Present worldwide:  Rippling muscle disease, Any age Myalgia, muscle rippling 
  private mutations usual dilated cardiomyopathy (rare)   
      
      
LGMD2A Calpain3 One of the most common   1st  2nd May present with 
  forms of AR-LGMD worldwide.   decade toe walking 
  Founder mutations in Basques   (2-40 years)  
  and in Eastern Europeans    
LGMD2B Dysferlin More common in Southern  MM, DMAT, proximal- 2nd  3rd Inability to walk on tiptoe. 
  than in Northern Europe distal phenotype from onset decade Calf pain and swelling 
    (10-73 years)  
      
      
LGMD2C -> 2F γ-, α-, β-, δ- Present worldwide.  1st - 2nd May present in Duchenne/ 
 sarcoglycan Founder mutations in   decade Becker like way 
  North Africans and Gypsies  (3-20 years)  
       
       
      
      
LGMD2G Telethonin Rarely reported outside  AD-dilated and hypertrophic 2nd decade Distal weakness and 
  Brazil cardiomyopathy  wasting may be present 
LGMD2H TRIM32 Only recently reported Sarcotubular myopathy,  2nd decade Possible mild facial 
  outside Hutterite population Bardet Biedl syndrome  weakness 
  of Canada
LGMD2I FKRP Relatively frequent in  Congenital muscular 1st  2nd Clinically may resemble 
  Northern Europe. Founder  dystrophy MDC1C decade Duchenne/ Becker MD 
  mutation in Northern  and intermediate (1-40 yrs)  
  Europeans phenotype    
      
      
LGMD2J Titin Reported only in Finland Heterozygotes have distal  1st decade History of distal weakness 
   myopathy. Other mutations  in heterozygotes 
   associated with 
   cardiomyopathy; 
   early onset myopathy with 
   severely progressive 
   cardiomyopathy   
LGMD2K POMT1 A few reported LGMD  Walker Warburg syndrome Birth  6 years May present early with 
  cases (Turkish and  and intermediate phenotypes  global delay, upper limb 
  English families)   weakness may be worse 
     than lower limb weakness.  
     Muscle hypertrophy 
     may be present
LGMD2L* Fukutin A few reported Fukuyama Congenital  < 1 year May present early with 
  LGMD cases Muscular Dystrophy;   global delay 
   Walker Warburg syndrome    
   and intermediate phenotypes; 
   dilated cardiomyopathy 1X   
LGMD2M* POMGnT1 Only one reported  Muscle-eye-brain disease 12 years May present early with 
  LGMD case   global delay 
LGMD2N* POMT2 A few reported Walker Warburg syndrome < 2 years Calf hypertrophy 
  LGMD cases and intermediate phenotypes    
LGMD2?* ? Reported in French ? 3rd decade Quadriceps atrophy may 
  Canadian families   be observed 
Bushby, et al.: Limb girdle muscular dystrophy
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Key features from Complications SpeciÞ c surveillance Creatine kinase levels
examination  and treatment
May be distal muscle Cardiomyopathy arrhythmia, Cardiac echo, ECG +/- Holter, Normal -10X
involvement respiratory failure FVC in sitting and lying.
  Treatment with pacing,
   respiratory support
Joint contractures, Arrhythmia, subsequent Cardiac echo, ECG +/- Holter, Normal -20X
rigid spine cardiomyopathy, respiratory FVC in sitting and lying.
 failure High risk of ventricular arryhythmia
  after pacing so implantable
  deÞ brillator indicated. Medical
   management of cardiomyopathy, 
  respiratory support 
PIRCs, rippling, Not reported with
muscle hypertrophy,  LGMD1C phenotype.
normal sporting ability  Dilated cardiomyopathy
in childhood phenotype is rare and distinct  3- 10X
Scapular winging,  Not frequent. Retained Contracture management 4-10X
contractures,  respiratory function can
muscle atrophy be a distinguishing
 feature of LGMD2A
Usually calf wasting, Not frequent. Cardiac  10-100X
biceps wasting.  impairment very rarely
Shoulder girdle weakness reported
usually later than proximal/ 
distal lower limb weakness 
May be muscle hypertrophy,  Cardiac echo and ECG  10-100X
Cardiomyopathy and respiratory failure after on annual basis, FVC
scapular winging conÞ nement to wheelchair particularly after loss
  of ambulation, pulse
  oximetry. Medical management 
  of cardiomyopathy, nocturnal 
  respiratory support
May be distal weakness Cardiac involvement was
 observed in one family  Normal -30X
Facial weakness can Not reported  Normal-20X
be observed
Muscle hypertrophy Cardiomyopathy and Cardiac echo and ECG on 10-100X
 respiratory failure annual basis, FVC in sitting
 (diaphragmatic) and lying at all ages, pulse
  possible even while  oximetry. Medical management
 still ambulant of cardiomyopathy, nocturnal 
  respiratory support
 Late respiratory  Normal-25X
 complications
   
Cognitive impairment,  Full spectrum of complications
microcephaly. possibly not yet appreciated
   -
Motor function Full spectrum of complications
deterioration during possibly not yet appreciated
infections
    -
Rapidly progressive Full spectrum of complications
 possibly not yet appreciated  -
May be cognitive impairment Full spectrum of complications
 possibly not yet appreciated 
 Full spectrum of complications  -
 possibly not yet appreciated
Table 2 Continued: The LGMDs: Clinical features and type-speciÞ c management
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with early inability to stand on tiptoe, and sometimes 
with sudden onset of calf pain and swelling seems to 
be almost pathognomonic for the diagnosis.[22] This 
group of patients in particular may be misdiagnosed 
as myositis, which appears to be non-responsive to 
steroids. 
LGMD2C->F (Sarcoglycanopathies)
Before the molecular analysis, sarcoglycanopathies 
were labeled severe childhood autosomal recessive 
muscular dystrophy (SCARMD) to describe children 
who showed a Duchenne-like clinical phenotype with 
an autosomal recessive mode of inheritance.[23] Similar 
to Duchenne and Becker muscular dystrophy, patients 
affected by sarcoglycanopathies frequently show 
calf and tongue hypertrophy. However, an important 
distinguishing factor from dystrophinopathies is the 
absence of any cognitive impairment, in all types of 
sarcoglycanopathies.
Alpha-sarcoglycanopathy (LGMD2D) tends to 
be clinically milder compared to the other 
sarcoglycanopathies[24,25] although no pathognomonic 
clinical features can distinguish the different 
sarcoglycanopathies. 
LGMD2G
LGMD2G or Telethoninopathy is a rare form of AR-
LGMD described only in a few Brazilian families. 
Clinically it appears to be characterized by mildly 
progressive proximal weakness in the upper and 
lower limbs and distal muscle involvement with foot 
drop. Calf hypertrophy is often present and can be 
asymmetric.[26]
LGMD2H
LGMD2H results from mutations in the TRIM32 gene 
and has been only recently described in non-Hutterite 
populations.[27-29] 
Alpha-dystroglycanopathies
Defects in the glycosylation of alpha-dystroglycan 
(alpha-DG) are classically associated with congenital 
muscular dystrophies (CMDs). However, over the last 
few years new LGMD phenotypes associated with 
mutations in the six known glycosyltransferase genes 
have been emerging.[30] In this context, the most common 
form of LGMD due to abnormal glycosylation of alpha-
DG is LGMD2I. It results from mutations in the Fukutin-
related protein gene (FKRP).[31,32] LGMD2I shows a high 
variability in clinical presentations, ranging from the 
severe Duchenne-like disease course to late-onset and 
slow progressive forms. Characteristic clinical features 
of this LGMD include calf and tongue hypertrophy. A 
response to steroid treatment (prednisolone) has been 
described in some patients with LGMD2I[33] and future 
clinical trials may clarify this observation.
Other LGMD phenotypes have been recently shown to 
be associated with mutations in other known or putative 
glycosyltransferase genes, in particular POMT1, 
POMT2, fukutin and POMGnT1.[34-37] The observation 
of such intermediate phenotypes between LGMDs 
and congenital muscular dystrophies, the structural 
or functional brain involvement in some of these 
new forms of LGMD and the pathogenic background 
complicate the classification of these new phenotypes 
and genetic entities.[38]
LGMD2J
LGMD2J is a severe form of autosomal recessive 
muscular dystrophy which so far has been described 
only in the Finnish population. It is characterized 
by onset in the first to third decade with progressive 
weakness of all proximal muscles. Facial muscles are not 
involved but some patients develop late distal muscle 
weakness.[39]
Associated complication
Muscular dystrophies are often multisystem disorders. 
Identification of associated complications can be 
helpful in the differential diagnosis of the different 
LGMD subtypes. Also, the recognition of a particular 
type of muscular dystrophy can help to assign a more 
precise risk of complications and to direct appropriate 
management and type-specific follow-up. The more 
frequent and severe complications in LGMDs include 
respiratory and heart involvement. The cardiovascular 
complications include the development of a progressive 
cardiomyopathy or arrhythmias, while respiratory 
complications may or may not have significant 
diaphragmatic weakness as a clear component of 
the problem. These complications are present at 
different frequencies within the various disorders 
in the LGMD group [Table 2]. Preserved respiratory 
and heart function is a distinguishing clinical feature 
of LGMD2A.[16] Restrictive respiratory abnormalities 
and cardiomyopathy with reduced ejection fraction 
are almost constantly associated with LGMD2I and 
sarcoglycanopathies, with the exception of LGMD2D 
which is rarely complicated by heart involvement.[10] 
These complications need to be sought specifically and 
an appropriate management of any detected problems 
may have a positive impact on the length and quality 
of life.[40,41]
The diagnostic Process [Figure 1]
The first step to diagnosing a particular type of LGMD 
is knowledge of the prior probability of seeing any one 
of the particular subtypes in a particular population . All 
of the LGMDs are individually rare and some of them 
have only been described in a few families. Moreover, 
their population frequency is highly variable and the 
Bushby, et al.: Limb girdle muscular dystrophy
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Figure 1: A diagnostic algorithm for achieving diagnosis in LGMD based on clinical, creatine kinase, muscle biopsy and molecular genetic testing. 
CK= creatine kinase, CK levels are given as a general guide to levels of CK likely at diagnosis, but this can vary from patient to patient and with 
disease progression. CK level A= normal or mild elevation (<10x normal) CK level B= moderate elevation (8- 40x normal) CK level C extreme elevation 
(>40x normal). Other abbreviations: ADEDMD- autosomal dominant Emery Dreifuss muscular dystrophy, EDMDX- X-linked Emery Dreifuss muscular 
dystrophy, PIRCs: percussion-induced repetitive contractions
prevalence of the different forms of LGMD differs 
between populations, depending on geographical and 
ethnic factors. There are some problems in comparing 
the prevalence of the different types of LGMD as the 
ways used to define the different entities (for example, 
by protein diagnosis or by a combination of protein 
and DNA studies) as well as the denominators for the 
different studies are not uniform.
In the Caucasian population the autosomal dominant 
forms of LGMD seem to be responsible for around 
14% of all cases but they are probably less common 
in other ethnicities.[11] LGMD2A seems to be the most 
frequent form of LGMD worldwide, though the relative 
frequency of the different autosomal recessive forms in 
different populations is still under investigation, and 
comparison from country to country is complicated by 
the fact that different studies report their findings in 
different ways.
In Brazil the relative proportion of the different forms 
among classified patients with AR-LGMD (through DNA 
and/or muscle protein analysis) from 120 families was 
found to be 32% for LGMD2A, 22% for LGMD2B, 32% 
for the sarcoglycanopathy group, 3% for LGMD2G and 
11% for LGMD2I.[42] In the Italian population, looking 
at both dominant and recessive diagnoses, LGMD2A 
was the most common with 28.4%, dysferlinopathy 
18.7%, sarcoglycanopathy 18.1%, LGMD2I 6.4%, 
LGMD1C 1.3% and undetermined diagnosis 27.1%. [43] 
In the North of England population, LGMD2A 
represented 26.5% of the whole LGMD group, LGMD2I 
19.1%, sarcoglycanopathy 11.7%, LGMD2B 5.9% and 
unclassified LGMD constituted 27.9% (Norwood et al., 
in preparation). In this population, LGMDs as a whole 
represented 6.15% of the total clinic population (when 
the most common diagnoses were myotonic dystrophy 
and dystrophinopathies). In Australia, calpainopathy 
represented 8% of a total muscular dystrophy 
population and dysferlinopathy 5%, while LGMD2I was 
less frequent (3%).[44] By contrast, LGMD2I represents a 
common type of LGMD in the German and Scandinavian 
populations.[45] The most common LGMDs in the 
United States are calpainopathies, dysferlinopathies, 
sarcoglycanopathies and dystroglycanopathies[46] 
with a distribution of immunophenotypes of 
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12% calpainopathy, 18% dysferlinopathy, 15% 
sarcoglycanopathy, 15% dystroglycanopathy and 
1.5% caveolinopathy. In the Netherlands, LGMD2A 
is the most frequent type of LGMD, consisting of 
21% of the classified families. LGMD2B is rare, while 
sarcoglycanopathies account for 16% of the classified 
families and of 69% of these have a severe, Duchenne 
like, autosomal recessive LGMD phenotype. LGMD2I 
consists of 8% of the genetically defined cases in this 
population.[47] Data from other populations are scanty 
given the lack in many areas of access to specialized 
diagnostic facilities. 
None of the different types of LGMD can be distinguished 
on basic muscle histology or electrophysiology. 
Electromyography may be useful in distinguishing this 
myopathic group of diseases from myotonic dystrophy 
Type2 (PROMM, DM2) which may be clinically similar. 
Morphological pattern of the muscle biopsy may be 
crucial in distinguishing LGMDs from Pompes disease 
or other metabolic syndromes. 
The serum creatine kinase (CK) is variably elevated 
in the different disorders and this may serve as a useful 
indicator to subdivide the different types of LGMD, 
though it is no more than a guide. As a rule of thumb, 
the autosomal recessive types of LGMD are typically 
associated with a much higher level of CK elevation 
than the dominant forms of LGMD, with the exception 
of LGMD1C. Among the recessive forms, LGMD2B, 2I 
and sarcoglycanopathies are usually associated with 
very high CK levels. 
Over the last few years muscle magnetic resonance 
imaging (MRI) has been increasingly applied in order to 
determine distinct patterns of muscle involvement and 
may represent a promising advance in the differential 
diagnosis of neuromuscular conditions and of the 
different forms of LGMD and in directing appropriate 
protein and genetic investigations.[15,48,49] 
Despite the new knowledge about the molecular 
basis of most of the LGMDs, a diagnostic approach 
exclusively based on genetic testing is not usually 
applicable as it is often inefficient and expensive. 
The muscle biopsy is unavoidable in most cases and 
still represents an informative and economic step in 
the diagnostic process. Diagnosis therefore relies on a 
combination of clinical assessment, specialized muscle 
immunoanalysis and genetic testing. In informative 
families, linkage analysis may be useful to identify 
the gene involved. Otherwise, protein analysis can be 
used to pinpoint the likely gene primarily involved, 
though often complex patterns of secondary protein 
involvement in addition to the primary defect can 
complicate this process. A wide range of antibodies 
needs to be applied and frequently immunolabeling 
of a muscle biopsy sample needs to be supplemented 
by immunoblotting in order to elucidate primary and 
secondary protein abnormalities. No studies compare 
open versus needle biopsies, although it is important 
to obtain sufficient tissue to allow a comprehensive 
analysis and meaningful interpretation[10] [Table 1]. 
Combining information from the clinical and biopsy 
details therefore allows a diagnostic algorithm to be 
suggested and this is presented in Figure 1. In Part 
1 of the algorithm the features which may suggest 
diagnosis of either LGMD2I or LGMD1B (neither of 
which can be definitively diagnosed by muscle biopsy) 
are described. Parts 2-4 describe the interpretation 
of the muscle biopsy findings together with clinical 
pointers which may lead to a suggestion of a genetic 
diagnosis which needs to be confirmed by testing. This 
diagnostic algorithm was previously published (EFNS 
guidelines). [10] DNA analysis is still the gold standard 
of diagnosis in LGMDs.
Autosomal dominant limb girdle muscular dystrophy 
In most of the autosomal dominant AD-LGMD, 
the muscle biopsy is uninformative and shows an 
unspecific pattern that can either resemble a myopathy 
or a muscular dystrophy. No specific antibodies for 
immunohistochemical and Western Blot analysis are 
so far available for the AD-LGMD, with the exception 
of caveolin3.
LGMD2A
Immunoblotting has been an accepted test required 
for the diagnosis of LGMD2A. 
However, there is variability in the quantity and 
function of calpain3 protein detected on immunoblots 
even for those patients with genetically confirmed 
LGMD2A. Secondary deficiencies of calpain3 have been 
described in several muscular dystrophies, including 
LGMD2B and LGMD2J. Moreover, a normal calpain3 
expression on immunoblot has been observed in some 
patients in whom calpain3 mutations were proven[50-53] 
and seems to be related to abnormal protein enzymatic 
activity. 
LGMD2B
In LGMD2B, qualitative and quantitative protein 
analysis on muscle sections by immunostaining and 
Western Blot typically shows complete or partial 
absence of dysferlin , which seems to be predictive of 
mutations in the DYSF gene.[43] There may also be a 
secondary reduction in the expression of calpain3 and 
caveolin3.[52-54] The presence of inflammatory infiltrates 
is encountered at times and patients with dysferlinopathy 
may be misdiagnosed with polymyositis.
Sarcoglycanopathies
In sarcoglycanopathies the immunofluorescence 
analysis of muscle biopsy shows combined or more 
rarely isolated reduction of alpha, beta, gamma and delta 
sarcoglycans. A concomitant reduction of dystrophin 
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and in same cases of dystroglycan expression can also 
be found, complicating the differential diagnosis with 
dystrophinopathies. In most cases immunofluorescence 
analysis or immunoblotting do not allow a reliable 
specific diagnosis because primary defects in a single 
sarcoglycan affect the expression of other sarcoglycans. 
A possible association between γ−sarcoglycan deficiency 
at the muscle biopsy and gene mutations has been 
reported[43] but so far, correct diagnosis requires genetic 
confirmation and analysis of several sarcoglycan genes 
may be necessary.
Alpha-dystroglycanopathies
The muscle biopsy immunostaining in patients 
with any alpha dystroglycanopathies usually shows a 
reduction in the dystroglycan expression if the antibody 
is directed against the carbohydrate moieties of alpha 
dystroglycan. The abnormal glycosylation pattern 
can also be detected on Western Blot. However, the 
commonly available antibodies can give unspecific 
results and the interpretation of the protein analysis 
may be difficult. Secondary reduction of laminin-
alpha-2 on immunolabeling has been reported in most 
of the patients with alpha dystroglycanopathies and can 
be helpful to recognize these LGMDs.[55,56]
Conclusion
Achieving a precise diagnosis in all patients is 
important to apply genetic counseling properly and to 
plan appropriate medical management. It will become 
increasingly important as new specific therapies are 
developed, and as trials of therapies in different types of 
LGMDs, including limited local gene therapy trials get 
under way. As diagnostic testing begins to be systematically 
applied in different countries, the epidemiology of these 
diseases can increasingly be understood, and a variable 
pattern of disease frequency will be elucidated. Therefore 
the future development of diagnostic testing and indeed 
therapeutic studies will need to take these regional 
differences into account. Particularly striking is the 
predominance of LGMD2I due to the common C826A 
mutation in Northern Europe,[18] compared to a relatively 
higher proportion of LGMD2A and LGMD2B cases in 
Southern Europe. A highly focused approach to LGMD 
diagnostics is already improving management and is going 
to become increasingly important in the future.
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